Diagnostics News and Research

RSS

Gold nanoparticles for cancer treatment

World Gold Council (WGC) has today published 'Gold for Good: Gold and nanotechnology in the age of innovation', a research paper detailing new scientific and technological innovations using gold. The report, which was produced in conjunction with Cientifica Ltd, the world's leading source of global business and investor intelligence about nanotechnologies, demonstrates how gold nanoparticles offer the potential to overcome many of the serious issues facing mankind over the coming decades.

12 Feb 2010

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

IBM today announced a Research collaboratory in Melbourne, Australia, where scientists from the Victorian Life Sciences Computational Initiative at the University of Melbourne and the IBM Research Computational Biology Center will use high performance computing – including IBM's Blue Gene supercomputer – to study human disease.

12 Feb 2010

Fourth-quarter and full-year 2009 results announced by Quidel

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2009.

12 Feb 2010

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

Nippon Product Acquisition commences tender offer to acquire outstanding shares of Home Diagnostics

Nipro Corporation, through its wholly-owned subsidiary Nippon Product Acquisition Corporation (the “Purchaser”), today commenced a cash tender offer to purchase all outstanding shares of Home Diagnostics, Inc. pursuant to an Agreement and Plan of Merger among Nipro, the Purchaser and Home Diagnostics dated February 2, 2010 (the “Merger Agreement”).

11 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

PwC: Companies in Life Sciences sector captured largest share of overall venture capital during 2009

Companies in the Life Sciences sector, which includes the biotechnology and medical device industries, captured the largest share of overall venture capital during 2009, reflecting the relative strength of the sector during the economic downturn, according to PricewaterhouseCoopers LLP (PwC).

11 Feb 2010

Biomagnetics Diagnostics to accelerate development of assay test cartridge for malaria, HIV/AIDS, hepatitis and TB

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.

11 Feb 2010

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of HDC's molecular diagnostic test for colon cancer. This test demonstrated a 93% Sensitivity and a 93% Specificity in a previous validation study.

11 Feb 2010

Strategic Diagnostics is now SDIX

Strategic Diagnostics Inc., a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic, and food safety applications, today announced it will be doing business as SDIX (Strategic Diagnostics Inc. d/b/a SDIX).

11 Feb 2010

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

The Catalysis Foundation for Health (Catalysis), a 501 (c) (3) non-profit entity dedicated to developing sustainable diagnostics for the developing world, announced today that it has received a $5 million grant from the Bill & Melinda Gates Foundation. The grant money will be used to discover new tuberculosis (TB) biomarkers that can be used to improve diagnostic tests and potentially develop more effective TB treatments.

10 Feb 2010

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ open new path to femtomedicine

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ has opened up the path to femtomedicine, an entirely new cancer diagnostics, it was reported today at First Global Congress on NanoEngineering for Medicine and Biology in Houston, TX.

10 Feb 2010

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

Sequenom, Inc., today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

10 Feb 2010

FDA announces initiative to reduce cancer risk from medical imaging procedures

The U.S. Food and Drug Administration today announced an initiative to reduce unnecessary radiation exposure from three types of medical imaging procedures: computed tomography (CT), nuclear medicine studies, and fluoroscopy.

10 Feb 2010

Racial disparities continue in U.S. cancer screening practices

The incidence of advanced breast cancer diagnosis among black women remained 30 percent to 90 percent higher compared to white women between 1992 and 2004, according to new findings by researchers at Fred Hutchinson Cancer Research Center. In addition, the disparity in the incidence of advance colorectal cancer actually widened over this time period as rates fell among whites but increased slightly among blacks.

9 Feb 2010

Abbott seeks U.S. approval for HE4 assay to monitor recurrence/progression of epithelial ovarian cancer

A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott's ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first automated HE4 test available in the United States.

9 Feb 2010

QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays

QIAGEN today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.

From QIAGEN Manchester Limited 8 Feb 2010

Quest Diagnostics to reaffirm 2010 guidance at the UBS 2010 Global Healthcare Services Conference

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the UBS 2010 Global Healthcare Services Conference in New York City. The presentation is scheduled for Wednesday, February 10, 2010 at 9:00 a.m. Eastern Time.

From Quest Diagnostics 6 Feb 2010

HDC partners with New York surgery center to develop new molecular diagnostic tests for pancreatic cancer

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to develop new molecular diagnostic tests for the early detection of pancreatic cancer. The Pancreas, Biliary and Liver Surgery Center is under the leadership of Drs. Michael Wayne, Franklin Kassim and Avram Cooperman.

6 Feb 2010

Biotechnology: The next medical revolution

A recent article in the Scandia Journal reported that biotechnology is helping to improve our knowledge of many devastating illnesses, and has armed patients and their doctors with exciting new diagnostics and treatments to battle disease.

5 Feb 2010

Diagnostics News and Research

Gold nanoparticles for cancer treatment

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

Fourth-quarter and full-year 2009 results announced by Quidel

FDA grants approval for Abbott's antiretroviral medication Norvir

Nippon Product Acquisition commences tender offer to acquire outstanding shares of Home Diagnostics

PAREXEL International, Proteome Sciences form biomarker alliance

PwC: Companies in Life Sciences sector captured largest share of overall venture capital during 2009

Biomagnetics Diagnostics to accelerate development of assay test cartridge for malaria, HIV/AIDS, hepatitis and TB

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Strategic Diagnostics is now SDIX

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ open new path to femtomedicine

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

FDA announces initiative to reduce cancer risk from medical imaging procedures

Racial disparities continue in U.S. cancer screening practices

Abbott seeks U.S. approval for HE4 assay to monitor recurrence/progression of epithelial ovarian cancer

QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays

Quest Diagnostics to reaffirm 2010 guidance at the UBS 2010 Global Healthcare Services Conference

HDC partners with New York surgery center to develop new molecular diagnostic tests for pancreatic cancer

Biotechnology: The next medical revolution

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News